CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

A randomized multicentre trial to compare revascularization with optimal medical therapy for the treatment of chronic total coronary occlusions Guidelines in review: Comparison of the 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes and the 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation Cardiac Troponin Elevation in Patients Without a Specific Diagnosis 2-Year Outcomes After Stenting of Lipid-Rich and Nonrich Coronary Plaques Cardiac monocytes and macrophages after myocardial infarction Efficacy and safety of rosuvastatin vs. atorvastatin in lowering LDL cholesterol : A meta-analysis of trials with East Asian populations A VOYAGER Meta-Analysis of the Impact of Statin Therapy on Low-Density Lipoprotein Cholesterol and Triglyceride Levels in Patients With Hypertriglyceridemia Development and validation of a simple risk score to predict 30-day readmission after percutaneous coronary intervention in a cohort of medicare patients Overall and Cause-Specific Mortality in Randomized Clinical Trials Comparing Percutaneous Interventions With Coronary Bypass Surgery: A Meta-analysis Successful catheter ablation of electrical storm after myocardial infarction
|<<... 50 51 52 53 54 55 56 ...>>|

Original Research2017 Nov 1;38(41):3056-3065.

JOURNAL：Eur Heart J. Article Link

Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation of evidence-based treatments: experiences from the SWEDEHEART registry 1995-2014

Szummer K, Wallentin L, Lindhagen L et al. Keywords: Registry, Myocardial infarction, Time-trends, Outcomes

FULL TEXT PDF

>CBS CBS 2019

> CBS 2019

> CBS 2019 注册

> CBS 2019 会议日程

> CBS 2019 学术征集

> CBS 2019 热点

 CBSMD

> CBSMD 网站注册

> 教育中心

> 荐读文献

> Top 10 阅读文献

> 文献导读
CBS 2019 CBS 2019 主席团 教育中心 科研动态
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top